HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. (30th April 2019)

• Record Type: Journal Article
• Authors: Prat, Aleix; Pascual, Tomás; De Angelis, Carmine; Gutierrez, Carolina; Llombart-Cussac, Antonio; Wang, Tao; Cortés, Javier; Rexer, Brent; Paré, Laia; Forero, Andres; Wolff, Antonio C; Morales, Serafín; Adamo, Barbara; Brasó-Maristany, Fara; Vidal, Maria; Veeraraghavan, Jamunarani; Krop, Ian; Galván, Patricia; Pavlick, Anne C; Bermejo, Begoña; Izquierdo, Miguel; Rodrik-Outmezguine, Vanessa; Reis-Filho, Jorge S; Hilsenbeck, Susan G; Oliveira, Mafalda; Dieci, Maria Vittoria; Griguolo, Gaia; Fasani, Roberta; Nuciforo, Paolo; Parker, Joel S; Conte, PierFranco; Schiff, Rachel; Guarneri, Valentina; Osborne, C Kent; Rimawi, Mothaffar F;
• Is Part Of: Journal of the National Cancer Institute. Volume 112:Number 1(2020)
• Page Start: 46
• Page End: 54
• Publication Date: 2019-04-30
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djz042
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: Background: Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy. Methods: A research-based PAM50 assay was applied in 422 HER2-positive tumors from five II–III clinical trials (SOLTI-PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, TBCRC023, TBCRC006, and PER-ELISA, all patients had early disease and were treated with neoadjuvant lapatinib or pertuzumab plus trastuzumab for 12–24 weeks. Primary outcome was pathological complete response (pCR). In EGF104900, 296 women with advanced disease were randomized to receive either lapatinib alone or lapatinib plus trastuzumab. Progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) were evaluated. Results: A total of 305 patients with early and 117 patients with advanced HER2-positive disease were analyzed. In early disease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively. Following lapatinib and trastuzumab, the HER2-E and ERBB2 (HER2-E/ERBB2)-high group showed a higher pCR rate compared to the rest (44.5%, 95% confidence interval [CI] = 35.4% to 53.9% vs 11.6%, 95% CI = 6.9% to 18.0%; adjusted odds ratio [OR] = 6.05, 95% CI = 3.10 to 11.80, P < .001). Similar findings were observed with neoadjuvant trastuzumab and pertuzumab (pCR rate of 66.7% in HER2-E/ERBB2-high, 95% CI = 22.3% to 95.7% vs 14.7% in others, 95% CI = 4.9% to 31.1%; adjusted OR = 11.60, 95% CI = 1.66 to 81.10, P = .01). In the advanced setting, the HER2-E/ERBB2-high group was independently associated with longer PFS (hazard ratio [HR] = 0.52, 95% CI = 0.35 to 0.79, P < .001); higher ORR (16.3%, 95% CI = 8.9% to 26.2% vs 3.7%, 95% CI = 0.8% to 10.3%, P = .02); and longer OS (HR = 0.66, 95% CI = 0.44 to 0.97, P = .01). Conclusions: Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-positive breast cancer.